Compare MSA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSA | KYMR |
|---|---|---|
| Founded | 1914 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.4B |
| IPO Year | N/A | 2020 |
| Metric | MSA | KYMR |
|---|---|---|
| Price | $181.20 | $70.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 24 |
| Target Price | ★ $185.25 | $105.35 |
| AVG Volume (30 Days) | 229.1K | ★ 682.9K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 3.07 | N/A |
| EPS | ★ 7.10 | N/A |
| Revenue | ★ $1,863,597,000.00 | $43,735,000.00 |
| Revenue This Year | $4.58 | $18.70 |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | $25.83 | ★ N/A |
| Revenue Growth | ★ 3.31 | N/A |
| 52 Week Low | $127.86 | $19.45 |
| 52 Week High | $185.54 | $103.00 |
| Indicator | MSA | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.35 | 42.21 |
| Support Level | $179.25 | $66.21 |
| Resistance Level | $185.54 | $72.86 |
| Average True Range (ATR) | 3.80 | 3.68 |
| MACD | 0.90 | -0.76 |
| Stochastic Oscillator | 81.22 | 29.99 |
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The products include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems. End markets include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company's reportable geographic segments are Northern North America; Latin America; Europe, Middle East & Africa; and Asia Pacific. The company's operating segments have been aggregated into three reportable segments: Americas, International, and Corporate. Geographically the company generates the majority of its revenue from the United States.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.